EyePoint, Inc.
EyePoint, Inc.
Join ActionIf you are an EyePoint, Inc. investor who suffered a loss and would like to learn more, you can provide your information below:
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In EyePoint To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in EyePoint between May 27, 2025 and August 14, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT) and reminds investors of the January 19, 2027 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) DURAVYU was less effective than Defendants had led investors to believe; (ii) accordingly, DURAVYU’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
Lead Plaintiff Deadline: January 19, 2027
Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). Or submit your information below to learn about your rights.